Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EBITDA (2016 - 2025)

Capricor Therapeutics has reported EBITDA over the past 15 years, most recently at -$30.7 million for Q4 2025.

  • Quarterly results put EBITDA at -$30.7 million for Q4 2025, down 397.08% from a year ago — trailing twelve months through Dec 2025 was -$105.7 million (down 166.21% YoY), and the annual figure for FY2025 was -$105.8 million, down 166.66%.
  • EBITDA for Q4 2025 was -$30.7 million at Capricor Therapeutics, down from -$25.1 million in the prior quarter.
  • Over the last five years, EBITDA for CAPR hit a ceiling of -$682511.0 in Q4 2023 and a floor of -$30.7 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$7.5 million (2022), compared with a mean of -$10.8 million.
  • Biggest five-year swings in EBITDA: surged 91.14% in 2023 and later plummeted 804.9% in 2024.
  • Capricor Therapeutics' EBITDA stood at -$6.2 million in 2021, then decreased by 24.19% to -$7.7 million in 2022, then surged by 91.14% to -$682511.0 in 2023, then plummeted by 804.9% to -$6.2 million in 2024, then crashed by 397.08% to -$30.7 million in 2025.
  • The last three reported values for EBITDA were -$30.7 million (Q4 2025), -$25.1 million (Q3 2025), and -$26.3 million (Q2 2025) per Business Quant data.